Literature DB >> 2490829

Effect of risk status on treatment criteria. Implications of hypertension trials.

W S Browner1, S B Hulley.   

Abstract

When deciding whether to treat a patient with hypertension, clinicians must balance the benefit of treatment against its adverse effects. In the absence of an interaction, the multiplicative model of risk implies that the absolute benefit of treatment is related to the underlying risk of an adverse outcome. Thus, each additional risk factor multiplies the absolute benefit of treating hypertension. Analyses of data from subgroups in clinical trials of hypertension treatment suggest that this model is usually valid. In contrast, the adverse effects of treatment are usually unrelated to other risk factors. Thus, the cutoff point for treatment differs in different individuals: setting a single treatment threshold and goal for the entire population is not appropriate. Patients who are at high absolute risk because of prior coronary artery disease or other risk factors have a greater potential absolute benefit, and such patients deserve a low threshold and goal, such as a diastolic blood pressure of 90 mm Hg. Conversely, persons at low risk, such as white women without other risk factors, do not require such aggressive management.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2490829     DOI: 10.1161/01.hyp.13.5_suppl.i51

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care.

Authors:  N C Campbell; L D Ritchie; J Thain; H G Deans; J M Rawles; J L Squair
Journal:  Heart       Date:  1998-11       Impact factor: 5.994

Review 2.  Risk factors for coronary heart disease. Selected recent epidemiological advances.

Authors:  S B Hulley
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  The effects of mild diastolic hypertension on the results of tests of cognitive function in adults 22 to 59 years of age.

Authors:  E J Pérez-Stable; T J Coates; R Halliday; P S Gardiner; W W Hauck
Journal:  J Gen Intern Med       Date:  1992 Jan-Feb       Impact factor: 5.128

4.  Screening for hypertension among older adults: a primary care "high risk" approach.

Authors:  Jacob John; Jayaprakash Muliyil; Vinohar Balraj
Journal:  Indian J Community Med       Date:  2010-01

5.  The framing effect of relative and absolute risk.

Authors:  D J Malenka; J A Baron; S Johansen; J W Wahrenberger; J M Ross
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

6.  Who can tolerate a marginal kidney? Predicting survival after deceased donor kidney transplant by donor-recipient combination.

Authors:  Sunjae Bae; Allan B Massie; Alvin G Thomas; Gahyun Bahn; Xun Luo; Kyle R Jackson; Shane E Ottmann; Daniel C Brennan; Niraj M Desai; Josef Coresh; Dorry L Segev; Jacqueline M Garonzik Wang
Journal:  Am J Transplant       Date:  2018-07-14       Impact factor: 8.086

7.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.